Abstract

Soumya S. P.*, Sinchu Yesudanam, Anusree S., Dr. William Arputha Sundar A. S. and Sam Jeeva Kumar E.

ABSTRACT

Infectious liver disease caused by the hepatitis C virus. There is no vaccine and it commonly becomes chronic. Traditional treatment is limited by frequent adverse effects and low efficacy. The current therapy for HCV infection, includes one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 weeks with pegylated interferone interferon alfa-2a (PEG-IFN-?) and ribavirin for 48 weeks. Sofosbuvir, a recently approved nucleotide analog, is a highly potent inhibitor of the NS5B polymerase in the Hepatitis C virus (HCV), and has shown efficacy in combination with several other drugs, with and without PEG-INF, against HCV. It offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.